Aging is the most significant risk factor for 92 age-related diseases. Through model organism experiments, we have identified novel targets and pathways that enable early intervention and treatment of five key clinical indications by reversing aging. These indications include globally recognized challenges such as COVID-19-induced pulmonary fibrosis, idiopathic pulmonary fibrosis, and interstitial pneumonia (diseases characterized by poor prognosis, high mortality, and lack of effective therapies), as well as widely studied anti-aging indications in dermatology, hair regeneration, and obesity. Currently, we have secured patents for molecular structures and experimental pathways, with structural optimization efforts underway.
COVID-19, not only poses significant threats to patient health during the acute phase, but also leads to long-term sequelae that have become a global concern. Studies indicate that some recovered patients continue to experience persistent symptoms such as fatigue, dyspnea, and cognitive dysfunction, severely compromising their quality of life. Targeted critical interventions for these sequelae are therefore imperative.
Idiopathic interstitial pneumonia (IIP) typically manifests as progressive cough and dyspnea of varying severity. Research into its pathological mechanisms aims to advance novel therapeutic strategies. Current interventions primarily include systemic anti-inflammatory therapies (e.g., corticosteroids), antifibrotic agents such as pirfenidone (Esbriet) and nintedanib (Ofev), and combination regimens with immunosuppressants.
Inflammatory skin diseases are a category of disorders caused by immune dysregulation, leading to the destruction of skin tissue. Common types include psoriasis and atopic dermatitis. Their pathogenic mechanisms involve abnormal activation of both innate and adaptive immunity, as well as an imbalance in inflammatory mediators. Traditional treatments encompass topical medications, systemic therapies, and phototherapy. In recent years, novel biologics and small-molecule drugs targeting specific pathogenic factors have significantly improved patient symptoms and demonstrated therapeutic potential.
As of 2024, over 250 million people in China face hair loss, which has become a public health concern impacting self-esteem and mental health. The regulation of hair regeneration involves the periodic control of hair follicle stem cells, coordinated action of multiple signaling pathways (e.g., Wnt/β-catenin), and modulation of the hair follicle microenvironment. Current interventions include pharmacological treatments (e.g., minoxidil), hair transplantation, and laser therapies. Emerging technologies such as stem cell therapy and gene editing (e.g., CRISPR-based targeting of AR gene variants) hold promise for future solutions.
Obesity is a global health issue closely linked to various chronic diseases. Its development involves dysregulation of multiple signaling pathways, including insulin signaling and inflammatory pathways. Targeting these pathways can effectively regulate fat metabolism and energy expenditure, aiding in weight loss and improving metabolic health. Current research shows that drugs such as GLP-1 receptor agonists demonstrate promising efficacy in obesity treatment.
Senolytics are a class of compounds that selectively induce apoptosis in senescent cells. The currently recognized 14 hallmarks of aging include: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, immune system decline, chronic inflammation (inflammaging), microbiome dysbiosis, Extracellular matrix changes and Psychosocial isolation.
All Contents ©2025 AAAR. All Rights Reserved.
